TRANSCEND-CKD试验:瑞他鲁肽治疗慢性肾脏病的原理、设计与基线特征
TRANSCEND-CKD是一项双盲、安慰剂对照的2b期机制研究,评估瑞他鲁肽在超重/肥胖合并CKD成人中的疗效。主要终点为基线至第24周碘海醇清除率测定的mGFR变化。共筛查367例,随机146例,基线平均mGFR 49.3 mL/min/1.73 m2。
要点
- 瑞他鲁肽为GIP/GLP-1/胰高血糖素受体激动剂,在肥胖和T2D中减重并降低HbA1c。
- 研究纳入eGFR 25-75 mL/min/1.73 m2的超重/肥胖CKD患者,伴或不伴T2D。
- 主要终点为第24周mGFR较基线变化,采用碘海醇清除率测定。
核心结论
- TRANSCEND-CKD旨在提供瑞他鲁肽对肾功能和结构影响的机制性证据。
- 其结果将为正在进行的心肾结局试验TRIUMPH-Outcomes(NCT06383390)提供临床信息。
研究设计与样本
- 双盲、安慰剂对照、2b期机制研究。
- 纳入超重/肥胖合并CKD成人,eGFR 25-75 mL/min/1.73 m2,伴或不伴T2D。
- 按1:1随机至每周一次瑞他鲁肽最大耐受剂量至12 mg或匹配安慰剂。
- 共筛查367例,随机146例。
主要发现
- 平均年龄65.1岁(SD 10.6),女性45.2%,白人69.9%。
- 平均体重101.1 kg(SD 20.6),BMI 35.7 kg/m2(SD 6.1)。
- T2D占37.7%,其平均HbA1c 7.1%(SD 1.1%);无T2D者HbA1c 5.7%(SD 0.3%)。
- 平均mGFR 49.3 mL/min/1.73 m2(SD 19.0),胱抑素C-based eGFR 49.6 mL/min/1.73 m2(SD 13.2),肌酐-based eGFR 64.2 mL/min/1.73 m2(SD 17.8)。
- 基线尿白蛋白/肌酐比值中位数14.0 mg/g(IQR 6.0-69.0),21.8%使用SGLT2抑制剂。
关键数值与推荐
- 主要终点:基线至第24周碘海醇清除率测定的mGFR变化。
- 次要目标包括MRI评估的肾脏血流动力学和体积测量,包括肾周和肾窦脂肪。
临床怎么用
- 瑞他鲁肽可能针对CKD相关病理生理通路,但需机制研究验证其对肾功能的影响。
- 该研究设计可为CKD合并肥胖/超重患者的代谢干预提供机制性证据。
局限性
- 本文为设计论文,未报告疗效或安全性结果。
- 样本量146例,以机制终点为主,非临床硬终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D). Retatrutide may also address key chronic kidney disease (CKD)-related pathophysiological pathways. Mechanism-of-action studies are needed to understand its effects on kidney function. METHODS: TRANSCEND-CKD is a double-blind, placebo-controlled, Phase 2b mechanistic study evaluating the efficacy of retatrutide in adults with overweight/obesity and CKD [estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2], with and without T2D. Participants were randomized 1:1 to once-weekly retatrutide maximum tolerated dose up to 12 mg or matched placebo. The primary objective is to evaluate the effect of retatrutide versus placebo on change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 24. Additional objectives include changes in magnetic resonance imaging-assessed kidney hemodynamic and volumetric measurements, including perirenal and renal sinus fat. RESULTS: Of 367 participants screened, 146 were randomized to study interventions. The mean age was 65.1 years [standard deviation (SD) 10.6], 45.2% were female and 69.9% were White. The mean weight was 101.1 kg (SD 20.6) and body mass index 35.7 kg/m2 (SD 6.1). Participants with T2D (37.7%) had a mean HbA1c of 7.1% (SD 1.1%), while HbA1c was 5.7% (SD 0.3%) in participants without T2D. The mean mGFR was 49.3 mL/min/1.73 m2 (SD 19.0), cystatin C-based eGFR was 49.6 mL/min/1.73 m2 (SD 13.2) and creatinine-based eGFR was 64.2 mL/min/1.73 m2 (SD 17.8). The median baseline urine albumin-to-creatinine ratio was 14.0 mg/g (interquartile range 6.0-69.0). A total of 21.8% of participants were treated with sodium-glucose cotransporter-2 inhibitors at baseline. CONCLUSIONS: TRANSCEND-CKD is designed to provide mechanistic insights on the effects of retatrutide on kidney function and structure, and to inform clinical findings in the ongoing cardio-kidney outcome trial TRIUMPH-Outcomes (NCT06383390). CLINICAL TRIAL REGISTRATION NUMBER: NCT05936151.
引用
- Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026. PMID: 41160422. doi:10.1093/ndt/gfaf230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。